Menu

Pharma News

Biologicals 1 V13D05

Samsung Biologics to spin-off Samsung Bioepis

Home/Pharma News | Posted 10/06/2025

In May 2025, South Korea’s Samsung Biologics announced that it will undergo split to separate its contract development and manufacturing organization (CDMO) business from its biosimilar and novel drug development business, Samsung Bioepis. Following this, the company announced that its CDMO arm has secured two contract manufacturing deals worth circa US$320 million with European and Asian pharmaceutical companies.

Pay for Delay DrugsMoneyGeneric V13F21

President Trump issues executive order to lower drug prices

Home/Pharma News | Posted 05/06/2025

On 15 April 2025, US President Donald J Trump issued an executive order aiming to lower prescription drug prices and improve accessibility for US patients.

143 AA010952

Cuba and Russia plan first joint biopharmaceutical venture in 2025

Home/Pharma News | Posted 27/05/2025

Cuba and Russia plan to establish their first joint venture in the biopharmaceutical sector in 2025, aiming to expand the presence of Cuban products in the Eurasian market and advance technological and scientific cooperation. The initiative comes as the two countries strengthen bilateral relations in strategic areas such as biotechnology and the pharmaceutical industry.

Immunology Serology V18D06

Sandoz–Henlius partner to commercialize oncology biosimilar ipilimumab

Home/Pharma News | Posted 11/05/2025

In April 2025, Sandoz announced that it has signed a global collaboration agreement with Shanghai Henlius Biotech (Henlius), to commercialize a biosimilar of leading oncology therapy, ipilimumab, referencing the originator of Bristol-Myers Squibb’s Yervoy.

Business Aquisition V13F07

Alvotech acquires Xbrane

Home/Pharma News | Posted 30/04/2025

On 20 March 2025, Alvotech announced the acquisition of Sweden’s Xbrane Biopharma AB’s (Xbrane) R & D operations and a biosimilar candidate XB003, a biosimilar to Cimzia (certolizumab pegol).

18 AA010920

Colombia boosts health sovereignty through public-private biotech collaboration agreement

Home/Pharma News | Posted 07/04/2025

On 27 February 2025, Colombia's Ministry of Health, the National Institute of Health, and VaxThera announced a pivotal agreement to enhance research, development, and production of biologicals and health technologies. This collaboration aims to strengthen health sovereignty, advance biotechnology, and improve emergency response capabilities.

Shaking hands V13D29

Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News | Posted 18/02/2025

Bio-Thera Solutions (Bio-Thera) has partnered with Tabuk Pharmaceutical Manufacturing (Tabuk) to exclusively manufacture, distribute, and market BAT2206, a biosimilar to Stelara (ustekinumab), in Saudi Arabia. Simultaneously, Bio-Thera expanded its collaboration with SteinCares, granting exclusive rights to distribute an additional biosimilar in Latin America, reinforcing its global biosimilar strategy.

01 AA007239

Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News | Posted 06/02/2025

Klinge Biopharma (Klinge) and Teva Pharmaceuticals (Teva) formed a semi-exclusive agreement for the commercialization of Formycon’s FYB203 biosimilar to Eylea (aflibercept) in Europe, while MS Pharma partners for the MENA (Middle East and North Africa) commercialization of FYB202, a biosimilar to Stelara (ustekinumab).

18 AA010920

Biosimilars thrive as China’s biotech industry gains momentum

Home/Pharma News | Posted 21/01/2025

China is emerging as a global biotech leader, attracting significant investment and partnerships from multinational pharmaceutical companies. Its innovative therapies and biosimilars are gaining international traction, reshaping the industry despite ongoing challenges.

66 AA010655

Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News | Posted 15/01/2025

The World Health Organization (WHO) has launched the ‘Greener Pharmaceuticals’ Regulatory Highway’ initiative to promote sustainability in the pharmaceutical sector. The initiative calls for innovative regulatory practices, sustainable manufacturing, and eco-friendly innovations to reduce the environmental impact of healthcare products.